vs
バイオマリン(BMRN)とUFP INDUSTRIES INC(UFPI)の財務データ比較。上の社名をクリックして会社を切り替えられます
UFP INDUSTRIES INCの直近四半期売上が大きい($1.3B vs $874.6M、バイオマリンの約1.5倍)。UFP INDUSTRIES INCの純利益率が高く(3.0% vs -5.3%、差は8.3%)。バイオマリンの前年同期比売上増加率が高い(17.0% vs -9.0%)。UFP INDUSTRIES INCの直近四半期フリーキャッシュフローが多い($82.7M vs $58.9M)。過去8四半期でバイオマリンの売上複合成長率が高い(16.1% vs -9.9%)
バイオマリン・ファーマシューティカルは米国カリフォルニア州サンラファエルに本社を置くバイオテクノロジー企業で、米国・南米・アジア・欧州に事業所や施設を保有する。中核事業は酵素補充療法の研究開発で、世界で初めてⅠ型ムコ多糖症治療薬ラロニダーゼとフェニルケトン尿症治療薬を提供した実績がある。
UFPインダストリーズはホールディングカンパニーで、小売、産業、建設の3つの市場に事業を展開しています。本社は米国ミシガン州グランドラピッズに所在し、1993年に上場。218の関連事業拠点を持ち、小売、建設、包装分野に数万点の製品を供給しています。
BMRN vs UFPI — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $874.6M | $1.3B |
| 純利益 | $-46.6M | $40.0M |
| 粗利率 | 68.5% | 16.3% |
| 営業利益率 | -5.1% | 4.4% |
| 純利益率 | -5.3% | 3.0% |
| 売上前年比 | 17.0% | -9.0% |
| 純利益前年比 | -137.3% | -41.3% |
| EPS(希薄化後) | $-0.22 | $0.71 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $874.6M | $1.3B | ||
| Q3 25 | $776.1M | $1.6B | ||
| Q2 25 | $825.4M | $1.8B | ||
| Q1 25 | $745.1M | $1.6B | ||
| Q4 24 | $747.3M | $1.5B | ||
| Q3 24 | $745.7M | $1.6B | ||
| Q2 24 | $712.0M | $1.9B | ||
| Q1 24 | $648.8M | $1.6B |
| Q4 25 | $-46.6M | $40.0M | ||
| Q3 25 | $-30.7M | $75.3M | ||
| Q2 25 | $240.5M | $100.7M | ||
| Q1 25 | $185.7M | $78.8M | ||
| Q4 24 | $124.9M | $68.0M | ||
| Q3 24 | $106.1M | $99.8M | ||
| Q2 24 | $107.2M | $125.9M | ||
| Q1 24 | $88.7M | $120.8M |
| Q4 25 | 68.5% | 16.3% | ||
| Q3 25 | 82.0% | 16.8% | ||
| Q2 25 | 81.8% | 17.0% | ||
| Q1 25 | 79.7% | 16.8% | ||
| Q4 24 | 81.8% | 16.4% | ||
| Q3 24 | 74.7% | 18.1% | ||
| Q2 24 | 81.7% | 19.1% | ||
| Q1 24 | 80.7% | 19.9% |
| Q4 25 | -5.1% | 4.4% | ||
| Q3 25 | -6.0% | 5.7% | ||
| Q2 25 | 33.5% | 6.7% | ||
| Q1 25 | 30.0% | 5.8% | ||
| Q4 24 | 21.6% | 5.4% | ||
| Q3 24 | 15.3% | 7.3% | ||
| Q2 24 | 16.9% | 8.4% | ||
| Q1 24 | 13.6% | 8.2% |
| Q4 25 | -5.3% | 3.0% | ||
| Q3 25 | -4.0% | 4.8% | ||
| Q2 25 | 29.1% | 5.5% | ||
| Q1 25 | 24.9% | 4.9% | ||
| Q4 24 | 16.7% | 4.7% | ||
| Q3 24 | 14.2% | 6.1% | ||
| Q2 24 | 15.1% | 6.6% | ||
| Q1 24 | 13.7% | 7.4% |
| Q4 25 | $-0.22 | $0.71 | ||
| Q3 25 | $-0.16 | $1.29 | ||
| Q2 25 | $1.23 | $1.70 | ||
| Q1 25 | $0.95 | $1.30 | ||
| Q4 24 | $0.65 | $1.12 | ||
| Q3 24 | $0.55 | $1.64 | ||
| Q2 24 | $0.55 | $2.05 | ||
| Q1 24 | $0.46 | $1.96 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $1.3B | $948.6M |
| 総負債低いほど良い | — | $229.8M |
| 株主資本純資産 | $6.1B | $3.1B |
| 総資産 | $7.6B | $4.0B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.08× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.3B | $948.6M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.2B | $874.0M | ||
| Q1 25 | $1.0B | $934.3M | ||
| Q4 24 | $942.8M | $1.2B | ||
| Q3 24 | $675.4M | $1.2B | ||
| Q2 24 | $972.1M | $1.1B | ||
| Q1 24 | $747.0M | $1.0B |
| Q4 25 | — | $229.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $234.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $6.1B | $3.1B | ||
| Q3 25 | $6.1B | $3.2B | ||
| Q2 25 | $6.0B | $3.1B | ||
| Q1 25 | $5.8B | $3.2B | ||
| Q4 24 | $5.7B | $3.2B | ||
| Q3 24 | $5.4B | $3.2B | ||
| Q2 24 | $5.3B | $3.1B | ||
| Q1 24 | $5.1B | $3.1B |
| Q4 25 | $7.6B | $4.0B | ||
| Q3 25 | $7.6B | $4.1B | ||
| Q2 25 | $7.5B | $4.1B | ||
| Q1 25 | $7.1B | $4.2B | ||
| Q4 24 | $7.0B | $4.2B | ||
| Q3 24 | $6.9B | $4.2B | ||
| Q2 24 | $7.1B | $4.1B | ||
| Q1 24 | $6.9B | $4.1B |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $99.6M | $146.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $58.9M | $82.7M |
| FCFマージンFCF / 売上 | 6.7% | 6.2% |
| 設備投資強度設備投資 / 売上 | 4.7% | 4.8% |
| キャッシュ転換率営業CF / 純利益 | — | 3.67× |
| 直近12ヶ月FCF直近4四半期 | $725.0M | $276.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $99.6M | $146.6M | ||
| Q3 25 | $368.7M | $286.0M | ||
| Q2 25 | $185.3M | $221.9M | ||
| Q1 25 | $174.4M | $-108.8M | ||
| Q4 24 | $185.6M | $144.9M | ||
| Q3 24 | $221.5M | $258.6M | ||
| Q2 24 | $118.8M | $255.9M | ||
| Q1 24 | $47.0M | $-16.8M |
| Q4 25 | $58.9M | $82.7M | ||
| Q3 25 | $340.2M | $210.2M | ||
| Q2 25 | $168.2M | $159.5M | ||
| Q1 25 | $157.6M | $-176.1M | ||
| Q4 24 | $166.1M | $78.1M | ||
| Q3 24 | $203.0M | $199.7M | ||
| Q2 24 | $97.4M | $198.4M | ||
| Q1 24 | $20.9M | $-65.9M |
| Q4 25 | 6.7% | 6.2% | ||
| Q3 25 | 43.8% | 13.5% | ||
| Q2 25 | 20.4% | 8.7% | ||
| Q1 25 | 21.2% | -11.0% | ||
| Q4 24 | 22.2% | 5.3% | ||
| Q3 24 | 27.2% | 12.1% | ||
| Q2 24 | 13.7% | 10.4% | ||
| Q1 24 | 3.2% | -4.0% |
| Q4 25 | 4.7% | 4.8% | ||
| Q3 25 | 3.7% | 4.9% | ||
| Q2 25 | 2.1% | 3.4% | ||
| Q1 25 | 2.3% | 4.2% | ||
| Q4 24 | 2.6% | 4.6% | ||
| Q3 24 | 2.5% | 3.6% | ||
| Q2 24 | 3.0% | 3.0% | ||
| Q1 24 | 4.0% | 3.0% |
| Q4 25 | — | 3.67× | ||
| Q3 25 | — | 3.80× | ||
| Q2 25 | 0.77× | 2.20× | ||
| Q1 25 | 0.94× | -1.38× | ||
| Q4 24 | 1.49× | 2.13× | ||
| Q3 24 | 2.09× | 2.59× | ||
| Q2 24 | 1.11× | 2.03× | ||
| Q1 24 | 0.53× | -0.14× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
UFPI
| Retail Segment | $444.0M | 33% |
| Structural Packaging | $230.2M | 17% |
| Factory Built | $189.7M | 14% |
| Site Built | $152.7M | 11% |
| Palletone Inc | $119.2M | 9% |
| Deckorators | $55.2M | 4% |
| Commercial | $53.2M | 4% |
| Concrete Forming | $44.2M | 3% |
| Transferred Over Time | $29.6M | 2% |
| Protective Packaging | $20.7M | 2% |